<p>新澤西州沃倫，2026 年 1 月 29 日（環球新聞通訊社）——Tevogen（“Tevogen Bio Holdings Inc.” 或 “公司”）（納斯達克：TVGN）今天宣佈，當前基於時間和個人表現的長期股票激勵計劃將進行修改，以使獎勵與公司設定的里程碑（包括收入）保持一致。更新後的計劃將適用於所有符合條件參與公司長期激勵計劃的員工、高管、董事和顧問。</p>
<p>Tevogen 創始人兼首席執行官 Ryan Saadi 博士評論道：“Tevogen 最初是一家 T 細胞治療生物科技公司，現已發展為一家多元化的醫療保健公司，包括可擴展的醫療保健人工智能項目。公司的目標是在 2030 年前推出至少四款重磅產品，並通過我們當前的項目、潛在的資產收購和合資企業在 2026 年實現收入增長。”</p>
<p><strong>關於 Tevogen</strong></p>
<p>Tevogen 是一家基於可負擔性、效率和科學嚴謹原則構建的下一代社會整合醫療企業。該公司利用行業領先的人工智能和精準 T 細胞治療平台，採用以患者為中心和成本控制的運營模式，並與全球技術領袖進行戰略合作，以支持在多個治療領域開發先進的、拯救生命的療法以及為更廣泛的醫療保健系統提供可擴展的解決方案。</p>
<p>Tevogen Bio 是公司的主要項目，已完成一項概念驗證臨牀試驗，證明其單 HLA 限制、基因未修飾的異體 T 細胞的潛力。Tevogen Bio 的產品線涵蓋病毒學、腫瘤學和神經學，基於公司的專有 ExacTcell™平台構建。</p>
<p>Tevogen.AI 旨在通過加速靶點檢測、幫助降低失敗率以及通過專有預測技術支持優化臨牀試驗設計來變革藥物開發。該平台利用來自領先技術提供商（包括微軟和 Databricks）的雲和數據服務，以推進其長期目標，即預測任何給定蛋白質-HLA 組合的蛋白質組，從而實現快速且成本高效的治療發現。</p>
<p>Tevogen 正在探索未來的戰略舉措，可能包括國內仿製藥、生物類似藥、醫療設備以及為醫療服務提供者提供創新保險解決方案。這些項目共同反映了 Tevogen 的使命，即通過更快、更高效和更公平的醫療模式推動可持續創新，擴大患者的獲取渠道。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含某些前瞻性聲明，包括但不限於與 Tevogen 的研究和製造能力的計劃、對未來增長的預期、對醫療保健和生物製藥行業的預期，以及 Tevogen 對其產品候選者在治療傳染病和癌症方面的開發、潛在益處和患者獲取的預期。前瞻性聲明有時可以通過 “可能”、“可以”、“將”、“期望”、“預期”、“可能”、“潛在”、“目標”、“機會”、“項目”、“相信”、“未來” 等詞語及其反義詞來識別。這些聲明基於管理層截至本新聞稿日期的期望、假設、估計、預測和信念，並受到多種因素的影響，包括已知和未知的風險、延遲、不確定性以及其他不在公司控制範圍內的因素，這些因素可能導致公司的實際結果、表現或成就與這些前瞻性聲明所表達或暗示的結果、表現或其他期望存在重大差異。</p>
<p>可能導致實際結果、表現或成就與前瞻性聲明所表達或暗示的結果存在差異的因素包括但不限於：Tevogen 所競爭市場的變化，包括其競爭格局、技術演變或監管變化；國內和全球經濟狀況的變化；Tevogen 可能無法執行其增長戰略或在管理其增長和擴展運營方面遇到困難的風險；Tevogen 可能無法開發和維持有效的內部控制的風險；未能實現 Tevogen 的商業化和開發計劃以及識別和實現額外機會的風險，這可能受到競爭、Tevogen 經濟增長和管理增長的能力以及招聘和留住關鍵員工等因素的影響；Tevogen 可能未能跟上快速的技術發展，以提供新的和創新的產品和服務，或在不成功的新產品和服務上進行大量投資的風險；Tevogen 將需要籌集額外資金以充分實現其商業計劃的風險；與開發、許可或收購新療法相關的風險；與 Tevogen 業務相關的監管訴訟或程序的風險；在執行、成本和完成臨牀前研究和臨牀試驗中固有的不確定性；與監管審查、批准和商業開發相關的風險；與知識產權保護相關的風險；Tevogen 有限的運營歷史；以及在 Tevogen 的 10-K 表格年度報告和隨後向 SEC 提交的文件中討論或引用的那些因素。</p>
<p>您不應對前瞻性聲明過於依賴，這些聲明僅在作出時有效。Tevogen 沒有義務更新任何前瞻性聲明，除非適用法律要求。</p>
<p><strong>聯繫方式</strong></p>
<p>Tevogen Bio 通訊部</p>
<p>電話：1 877 TEVOGEN，分機 701</p>
<p>Communications@Tevogen.com</p>
<p>與此公告相關的照片可在 https://www.globenewswire.com/NewsRoom/AttachmentNg/234bc63b-1117-4834-bedc-d86dbafb934d 獲取</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME5UWXlOQ00zTkRBd01UUTRJekl5T0RrNU1UYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME5UWXlOQ00zTkRBd01UUTRJekl5T0RrNU1UYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MThlYmUzNWItMzM0NC00MGU5LTk0NTQtNzVmMTFmM2I3MzIyLTEzMDE0NjctMjAyNi0wMS0yOS1lbg==/tiny/Tevogen-Bio-Inc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MThlYmUzNWItMzM0NC00MGU5LTk0NTQtNzVmMTFmM2I3MzIyLTEzMDE0NjctMjAyNi0wMS0yOS1lbg==/tiny/Tevogen-Bio-Inc.png"/></p>

醫藥突破 ETF - ALPS

TVGN

生物科技 ETF - VanEck Vectors

標普生物技術 ETF - SPDR

動態生物技術與基因組 ETF - Invesco

IBBQ

2 倍做多納斯達克生物技術 ETF - ProShares

紐交所高增長板生物技術指數 ETF - First Trust

納斯達克生物科技指數 ETF - iShares Nasdaq

TVGNW

<p>Tevogen Bio Holdings Inc.（納斯達克代碼：TVGN）宣佈對其長期股票激勵計劃進行修改，以使獎勵與公司里程碑（包括收入）保持一致。該更新的計劃將適用於所有符合條件的員工，旨在支持公司到 2030 年推出四款重磅產品的目標。Tevogen 正在發展成為一家多元化的醫療保健公司，利用人工智能和精準 T 細胞療法在多個治療領域開發先進療法。該公司還在探索仿製藥、生物類似藥和創新保險解決方案的戰略舉措</p>

<p>WARREN, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that the current time- and individual performance-based long-term stock incentive program will be modified to align awards with defined company milestones including revenue. The updated program will be applicable to all employees, officers, directors and consultants who are eligible to participate in the Company’s long term incentives plan.</p>
<div class="lb-trans"><p>新澤西州沃倫，2026 年 1 月 29 日（環球新聞通訊社）——Tevogen（“Tevogen Bio Holdings Inc.” 或 “公司”）（納斯達克：TVGN）今天宣佈，當前基於時間和個人表現的長期股票激勵計劃將進行修改，以使獎勵與公司設定的里程碑（包括收入）保持一致。更新後的計劃將適用於所有符合條件參與公司長期激勵計劃的員工、高管、董事和顧問。</p>
</div><p>Tevogen Founder and CEO, Dr. Ryan Saadi, commented, “Tevogen began as a T cell therapy biotech and has since evolved into a diversified healthcare company, including a scalable healthcare AI initiative. The Company’s goal is to launch at least four blockbuster products by 2030, and to pursue revenue generation in 2026 through our current programs, potential asset acquisitions, and joint ventures.”</p>
<div class="lb-trans"><p>Tevogen 創始人兼首席執行官 Ryan Saadi 博士評論道：“Tevogen 最初是一家 T 細胞治療生物科技公司，現已發展為一家多元化的醫療保健公司，包括可擴展的醫療保健人工智能項目。公司的目標是在 2030 年前推出至少四款重磅產品，並通過我們當前的項目、潛在的資產收購和合資企業在 2026 年實現收入增長。”</p>
</div><p><strong>About Tevogen</strong></p>
<div class="lb-trans"><p><strong>關於 Tevogen</strong></p>
</div><p>Tevogen is a next-generation, socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages industry-leading artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and strategic engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.</p>
<div class="lb-trans"><p>Tevogen 是一家基於可負擔性、效率和科學嚴謹原則構建的下一代社會整合醫療企業。該公司利用行業領先的人工智能和精準 T 細胞治療平台，採用以患者為中心和成本控制的運營模式，並與全球技術領袖進行戰略合作，以支持在多個治療領域開發先進的、拯救生命的療法以及為更廣泛的醫療保健系統提供可擴展的解決方案。</p>
</div><p>Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. The Tevogen Bio pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.</p>
<div class="lb-trans"><p>Tevogen Bio 是公司的主要項目，已完成一項概念驗證臨牀試驗，證明其單 HLA 限制、基因未修飾的異體 T 細胞的潛力。Tevogen Bio 的產品線涵蓋病毒學、腫瘤學和神經學，基於公司的專有 ExacTcell™平台構建。</p>
</div><p>Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.</p>
<div class="lb-trans"><p>Tevogen.AI 旨在通過加速靶點檢測、幫助降低失敗率以及通過專有預測技術支持優化臨牀試驗設計來變革藥物開發。該平台利用來自領先技術提供商（包括微軟和 Databricks）的雲和數據服務，以推進其長期目標，即預測任何給定蛋白質-HLA 組合的蛋白質組，從而實現快速且成本高效的治療發現。</p>
</div><p>Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.</p>
<div class="lb-trans"><p>Tevogen 正在探索未來的戰略舉措，可能包括國內仿製藥、生物類似藥、醫療設備以及為醫療服務提供者提供創新保險解決方案。這些項目共同反映了 Tevogen 的使命，即通過更快、更高效和更公平的醫療模式推動可持續創新，擴大患者的獲取渠道。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.</p>
<div class="lb-trans"><p>本新聞稿包含某些前瞻性聲明，包括但不限於與 Tevogen 的研究和製造能力的計劃、對未來增長的預期、對醫療保健和生物製藥行業的預期，以及 Tevogen 對其產品候選者在治療傳染病和癌症方面的開發、潛在益處和患者獲取的預期。前瞻性聲明有時可以通過 “可能”、“可以”、“將”、“期望”、“預期”、“可能”、“潛在”、“目標”、“機會”、“項目”、“相信”、“未來” 等詞語及其反義詞來識別。這些聲明基於管理層截至本新聞稿日期的期望、假設、估計、預測和信念，並受到多種因素的影響，包括已知和未知的風險、延遲、不確定性以及其他不在公司控制範圍內的因素，這些因素可能導致公司的實際結果、表現或成就與這些前瞻性聲明所表達或暗示的結果、表現或其他期望存在重大差異。</p>
</div><p>Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.</p>
<div class="lb-trans"><p>可能導致實際結果、表現或成就與前瞻性聲明所表達或暗示的結果存在差異的因素包括但不限於：Tevogen 所競爭市場的變化，包括其競爭格局、技術演變或監管變化；國內和全球經濟狀況的變化；Tevogen 可能無法執行其增長戰略或在管理其增長和擴展運營方面遇到困難的風險；Tevogen 可能無法開發和維持有效的內部控制的風險；未能實現 Tevogen 的商業化和開發計劃以及識別和實現額外機會的風險，這可能受到競爭、Tevogen 經濟增長和管理增長的能力以及招聘和留住關鍵員工等因素的影響；Tevogen 可能未能跟上快速的技術發展，以提供新的和創新的產品和服務，或在不成功的新產品和服務上進行大量投資的風險；Tevogen 將需要籌集額外資金以充分實現其商業計劃的風險；與開發、許可或收購新療法相關的風險；與 Tevogen 業務相關的監管訴訟或程序的風險；在執行、成本和完成臨牀前研究和臨牀試驗中固有的不確定性；與監管審查、批准和商業開發相關的風險；與知識產權保護相關的風險；Tevogen 有限的運營歷史；以及在 Tevogen 的 10-K 表格年度報告和隨後向 SEC 提交的文件中討論或引用的那些因素。</p>
</div><p>You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.</p>
<div class="lb-trans"><p>您不應對前瞻性聲明過於依賴，這些聲明僅在作出時有效。Tevogen 沒有義務更新任何前瞻性聲明，除非適用法律要求。</p>
</div><p><strong>Contacts</strong></p>
<div class="lb-trans"><p><strong>聯繫方式</strong></p>
</div><p>Tevogen Bio Communications</p>
<div class="lb-trans"><p>Tevogen Bio 通訊部</p>
</div><p>T: 1 877 TEVOGEN, Ext 701</p>
<div class="lb-trans"><p>電話：1 877 TEVOGEN，分機 701</p>
</div><p>Communications@Tevogen.com</p>
<div class="lb-trans"><p>Communications@Tevogen.com</p>
</div><p>A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/234bc63b-1117-4834-bedc-d86dbafb934d</p>
<div class="lb-trans"><p>與此公告相關的照片可在 https://www.globenewswire.com/NewsRoom/AttachmentNg/234bc63b-1117-4834-bedc-d86dbafb934d 獲取</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME5UWXlOQ00zTkRBd01UUTRJekl5T0RrNU1UYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY0NTYyNCM3NDAwMTQ4IzIyODk5MTc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MThlYmUzNWItMzM0NC00MGU5LTk0NTQtNzVmMTFmM2I3MzIyLTEzMDE0NjctMjAyNi0wMS0yOS1lbg==/tiny/Tevogen-Bio-Inc.png" alt="" original-src="https://ml.globenewswire.com/media/MThlYmUzNWItMzM0NC00MGU5LTk0NTQtNzVmMTFmM2I3MzIyLTEzMDE0NjctMjAyNi0wMS0yOS1lbg==/tiny/Tevogen-Bio-Inc.png"/></p>

Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue | TVGN Stock News

StockTitan

Tevogen Bio

Invesco Nasdaq Biotechnology ETF

TEVOGEN BIO HOLDINGS INC C/WTS 14/02/2029 (TO PUR COM)

Tevogen 將長期股票激勵計劃與公司里程碑對齊，其中包括收入 | TVGN 股票新聞